Design Highlights
- Starting in 2026, eligible Medicare enrollees can access GLP-1 weight loss drugs for a $50 monthly copayment after meeting deductibles.
- Coverage targets patients with a BMI of 35 or higher, or 27 with additional clinical criteria, requiring prior authorization.
- Financial strain may arise due to copayments and other independent expenses, especially with affordability thresholds set at 9.02% of household income.
- Coverage restrictions exist, with specific drugs like Ozempic and Wegovy limited by health conditions, complicating access for some patients.
- Medicare plans to invest $15.2 billion in GLP-1 drugs, aiming to combat obesity among older Americans and promote healthier living.
Medicare is shaking things up with a new option for weight loss drugs. That’s right, folks. Starting in 2026, Medicare will let some of its enrollees access GLP-1 drugs—those injectable miracle workers like Mounjaro, Ozempic, and Wegovy. It’s about time, right? After all, who wouldn’t want a shot at tackling obesity without breaking the bank? The federal government is even throwing in $245 a month for participating plans. So, what’s the catch?
Well, let’s get real. There’s always a catch. Enrollees will face a $50 monthly copayment after meeting their deductibles. Sounds manageable until you realize that these drugs were previously off-limits under the 2003 Medicare Modernization Act, which banned coverage for weight loss medications. It’s like being told you can have cake at a party, but only if you bring your own forks. Sure, it’s a step in the right direction, but it’s still a bit frustrating.
Enrollees will face a $50 monthly copayment, making access to weight loss drugs a bittersweet victory after years of restrictions.
The coverage starts with a short-term “Medicare GLP-1 Bridge” program in 2026 for approved drugs like Wegovy and Zepbound. Medicaid coverage for GLP-1s may begin as early as May 2026, which could enhance access for those in need.
Then, in January 2027, a multi-year demonstration program kicks in for Part D plans and Medicare Advantage.
Unfortunately, it’s not a free-for-all. Patients must have a BMI of 35 or higher to qualify. Or, if you’re not quite there, a BMI of 27 plus some other clinical criteria could do the trick. But good luck with the prior authorization dance—doctors will need to jump through hoops to get those prescriptions approved. For context, federal affordability thresholds for health insurance are set at 9.02% of household income for 2025, meaning even modest copayments can strain tight budgets.
And let’s not forget the pecking order of drugs. Ozempic? Sure, you can get that for type 2 diabetes but not for weight loss alone. That’s a hard pill to swallow. Wegovy is only covered if you have cardiovascular issues, even though it’s marketed for weight management. Zepbound? Sorry, it’s a no-go for weight management despite being approved for obesity. Confused yet? Welcome to the world of Medicare.
But wait, there’s more! Medicare is spending a whopping $15.2 billion on GLP-1s. Yes, billion. That’s a big price tag for a system that’s just now catching up with the obesity epidemic. The model aims to increase access to medications that could change lives.
Still, the new model aims to promote healthier living and expand access to medications that could change lives. So, maybe there’s hope yet. It’s a complicated mess, sure, but at least it’s a start. Here’s hoping it all pans out for the older Americans who need it most.
